Key result
Betaxolol and atenolol suppress adrenaline-induced but not digitalis-induced arrhythmias in canine models.
Why the study?
Does betaxolol suppress ventricular arrhythmias in canine models compared to atenolol?
Does betaxolol suppress ventricular arrhythmias in canine models compared to atenolol?
Betaxolol and atenolol effectively suppress adrenaline-induced but not digitalis-induced ventricular arrhythmias in canine models, suggesting clinical utility for arrhythmias related to increased sympathetic tone.
Should not change clinical arrhythmia management; leaves open translation of model-specific beta-blocker effects to human arrhythmias.
Antiarrhythmic effects of a new beta 1 selective adrenoceptor blocker, betaxolol, were examined in comparison with those of atenolol using two canine ventricular arrhythmia models (adrenaline arrhythmia and digitalis arrhythmia). Both betaxolol and atenolol suppressed adrenaline arrhythmia, and the minimum effective plasma concentration of betaxolol for this arrhythmia model was determined to be less than 10 ng/ml. However, on digitalis arrhythmia, both beta blockers were ineffective, even though the high doses used in these experiments, 3 mg/kg for betaxolol and 5 mg/kg for atenolol, showed significant hypotensive effects. The present results suggest that betaxolol and atenolol may be expected to be clinically effective on arrhythmias related to increased sympathetic tone.
No takes yet. Share an insight, caveat, or question.
MITSUHASHI et al. (1987) studied Ventricular arrhythmias (canine models). Betaxolol vs. Atenolol was evaluated on Suppression of adrenaline and digitalis arrhythmias. Betaxolol and atenolol both suppressed adrenaline-induced arrhythmias in canine models, but were ineffective against digitalis-induced arrhythmias despite significant hypotensive effects at high doses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: